Filter
159
Text search:
Bedaquiline
Featured
Recommendations
28
New Publications
51
Language
Document type
No document type
109
Studies & Reports
17
Guidelines
16
Manuals
8
Fact sheets
5
Situation Updates
2
Training Material
1
Strategic & Response Plan
1
Countries / Regions
Western and Central Europe
16
Eastern Europe
14
India
12
Uganda
3
Asia
3
Ethiopia
2
Germany
2
South Africa
2
South–East Asia Region
2
Latin America and the Carribbean
2
Eastern Europe and Central Asia
2
Russia
2
Nigeria
1
Philippines
1
Nepal
1
Zambia
1
Kenya
1
Bangladesh
1
Malawi
1
Namibia
1
Ukraine
1
Botswana
1
Paraguay
1
Estonia
1
Romania
1
Georgia
1
Global
1
Authors & Publishers
Publication Years
Category
Countries
35
Clinical Guidelines
32
Public Health
2
Pharmacy & Technologies
2
Key Resources
1
Toolboxes
TB
115
HIV
5
AMR
4
Pharmacy
4
Polio
3
Caregiver
2
NTDs
2
Global Health Education
1
COVID-19
1
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB,
...
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58
People living with HIV who have a low CD4 count are at a much higher risk of falling ill from TB infection than HIV negative people.
It is important to offer both HIV testing to TB patients and TB diagnosis in HIV patients. Early detection and effective treatment are essential to preventing TB
...
В борьбе с туберкулезом достигнуты значительные прорывы, среди которых ускоренные и более точные методы диагностики и первые новые лекарственные средства за 50 л
...
Цель настоящего документа («Основные положения») заключается в подготовке рекомендаций относительно необходимых на национальном уровне мер по адаптации стратег
...
Для создания этого отчета MSF исследовала программы и практику лечения лекарственно-чувствительного и лекарственно-устойчивого туберкулеза в восьмистранах с высо
...
Исследование этого года основано на предыдущем отчете. В нем отслеживается утверждение последних стратегий, руководств и методов в пяти сферах: диагностика и иссл
...
В настоящем отчете (это уже четвертое его издание) анализируются препятствия и факторы, затрудняющие доступ к препаратам для лечения лекарственно-устойчивого туб
...
Global Tuberculosis Report 2021
recommended
Each year, the WHO Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.
The
...
Frontiers in Pediatrics | www.frontiersin.org
1 April 2019 | Volume 7 | Article 159
Topics in Antiviral Medicine 25 Issue 2 May/June 2017
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr
...
The Antimicrobial Resistance Benchmark has evaluated for the second time how the most important players in the antibiotic market are addressing the rise of resistance and the global need for appropriate access to antibiotics. Although we can see progress — it’s hanging by a thread.
We have reac
...
6 July 2021. Three new nucleic acid amplification test (NAAT) classes are endorsed by WHO and included.
The latest operational handbook includes the new classes recommended by WHO. It aims at facilitating the implementation of the WHO recommendations by the Member States, technical partners, and ot
...
Assurer des prestations optimales dans la chaîne de soins destinés aux patients tuberculeux
Deuxième édition - Juin 2018
The Global Strategy for Tuberculosis Research and Innovation will support the efforts of governments and other stakeholders to accelerate TB research and innovation, and improve equitable access to the benefits of research.
Availabl in Arabic, Chinese, English, French, Spanish and Russian
